DiaMedica Therapeutics opened lower at $9.53, compared with its previous close of $9.66. In the last trading session, the stock traded between $9.05 and $9.59. It showed a downward intraday trend.
An investment of $100 made 5 years ago in DiaMedica Therapeutics is now worth
$ 206.27
Giving a profit of
$ 106.27 (106.27%)
Note: Past profits do not guarantee future returns.
Rating from 1 Analysts
Today's Change
$-0.32 (-3.27%)
Day High
$9.59
Day Low
$9.05
Day Open
$9.53
Prev Close
$9.66
Volume
1,41,850
1W Return
-13.39%
1M Return
13.74%
3M Return
36.53%
6M Return
44.87%
1Y Return
46.23%
Market Cap ($ Mn)
504
PE Ratio
-
PB Ratio
9.02
PEG Ratio
-
ROE
-78.17%
ROCE
-77.77%
EPS (TTM)
$-0.19
1 Week
-13.39%
1 Month
13.74%
3 Months
36.53%
6 Months
44.87%
9 Months
12.58%
DiaMedica Q3FY27 Results: Net loss widens to $11.3 million
Net loss widened to $11.3 million in Q3FY27 from $8.6 million in Q3FY26. R&D expenses increased 43.8% YoY to $9.2 million due to clinical trial expansion. ReMEDy2 stroke trial enrollment surpassed 200 participants; interim analysis expected Q1 2027. Cash position stands at $34.9 million, funding operations into Q4 2027. Regulatory authorizations received in Canada and Europe for early-onset preeclampsia study.
TodayDiaMedica Therapeutics joins four September investor conferences
DiaMedica Therapeutics (NASDAQ: DMAC) will attend four investment bank conferences in New York in September 2026. CEO Rick Pauls and CMO Dr. Julie Krop will hold a fireside chat at the Cantor Global Healthcare Conference on September 11. Rick Pauls will deliver a company presentation at the HC Wainwright Global Investment Conference on September 15. The firm focuses on developing DM199, a recombinant KLK1 protein treatment for preeclampsia and acute ischemic stroke.
2mo agoDiaMedica Q2 net loss widens to $10.1M as DM199 shows clinical promise
DiaMedica Therapeutics Inc. reported a second-quarter 2026 net loss of $10.1 million, widening from $7.7 million in the prior year period, driven by a 41% increase in R&D expenses to $8.2 million. The company holds $43.5 million in cash, providing a runway through 2027, while delivering key clinical milestones for its lead candidate DM199, including statistically significant blood pressure reductions in late-onset preeclampsia and completed enrollment for the first cohort of its fetal growth restriction trial.
3mo agoDiaMedica grants 160,000 options to new employee
DiaMedica Therapeutics Inc. granted 160,000 stock options to a new non-executive employee at $7.64 per share as an employment inducement. The options, approved by the Compensation Committee, vest over a ten-year period with specific milestones. This action was taken under Nasdaq Listing Rule 5635(c)(4) and the company's 2021 Employment Inducement Incentive Plan.
3mo agoDiaMedica plans rat study to address FDA feedback on DM199
DiaMedica Therapeutics Inc. received FDA feedback requiring additional nonclinical reproductive toxicity data for DM199. The company plans a rat PK study to support a U.S. IND application and will initiate preeclampsia studies in Canada and the UK.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in DiaMedica Therapeutics is now worth
$ 206.27
Giving a profit of
$ 106.27 (106.27%)
Note: Past profits do not guarantee future returns.
